Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.
The steroid receptor content of the primary endometrial cancer of 22 patients who were treated for recurrent or advanced disease has been measured and correlated with response to medroxyprogesterone acetate. No patient with a progesterone receptor (PR)-negative tumor responded and only 2 patients with PR-positive tumors responded, perhaps related to the low levels of PR in the tumors. It waits to be assessed whether receptor status is as good a guide to response to hormone therapy as tumor differentiation, site of recurrence, or disease-free interval.
Quinn
M A
MA
Cauchi
M
M
Fortune
D
D
D000230:Adenocarcinoma / Q000032:analysis / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011960:Receptors, Estrogen / Q000032:analysis*; D014594:Uterine Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000556:secondary
D011960:Receptors, Estrogen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone